(Total Views: 852)
Posted On: 08/08/2020 11:37:13 PM
Post# of 153988
Re: thriftycents #47976
There will be a clinical study report with more information than most of us will be able to appreciate.
Time to clinical resolutions and to return to normal activity are both endpoints. Those should both capture earlier improvement with Leronlimab vs. placebo.
The clinically interesting endpoints, at least to me are the change in the NEWS2 score, indicence of mechanical ventilation and death.
It appears anecdotally to me as an outsider at least, that a number of patients in mild/moderate do progress to becoming seriously ill. It is hard to know how well that will be captured in a small study, but the significant number of placebo SAEs argues that not everyone gets better by 14 days.
Time to clinical resolutions and to return to normal activity are both endpoints. Those should both capture earlier improvement with Leronlimab vs. placebo.
The clinically interesting endpoints, at least to me are the change in the NEWS2 score, indicence of mechanical ventilation and death.
It appears anecdotally to me as an outsider at least, that a number of patients in mild/moderate do progress to becoming seriously ill. It is hard to know how well that will be captured in a small study, but the significant number of placebo SAEs argues that not everyone gets better by 14 days.
(2)
(0)
